Head of Investor Relations. Industry: Biotech & Pharmaceuticals. 2020-2021 CytivaFor local office contact information, visit cytiva.com/contact CY12753-17Aug21-IG Evaluate Pharma. The Cytiva Global Biopharma Resilience Index is built using data from a survey of 1,165 respondents across 20 different countries, with 95% of responses coming from pharma and biopharma executives . Rainer M. Blair, President and Chief Executive Officer, stated, "For the full year 2020, we achieved nearly 10% core revenue growth including Cytiva, strong margin expansion, and more than $5 billion of free cash flow. Partially offsetting any resulting headwind in 2020, we expect continued Cytiva is bringing our long-standing expertise to the . For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has excluded the paid and anticipated MCPS cash dividends and assumed the "if-converted" method of share dilution (the incremental shares of common stock deemed outstanding applying the "if-converted" method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular period are referred to as the "Converted Shares") for any MCPS that were anti-dilutive for the given period. For the fourth quarter 2020, revenues increased 39.0% year-over-year to $6.8 billion, with 15.5% non-GAAP core revenue growth including Cytiva. We also present "base business" core revenue growth to demonstrate our core revenue growth and our core revenue growth including Cytiva excluding core sales growth directly attributable to COVID-19 and its impact. AMERSHAM, United Kingdom, April 1, 2020 /PRNewswire/ -- Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics,. Loss on early extinguishment of debt resulting from "make-whole" payments and deferred costs associated with the retirement of the 2022 Euronotes in both the three-month period and the year ended December 31, 2020, ($26 million pretax as reported in this line item, $20 million after-tax). Training for Innovative Behavior 2020 Publication: IBAM Training for Innovative behavior 2020 Publication . See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures, Core Sales Growth and Core Sales Growth Including Cytiva, % Change Three-Month Period Ended December 31, 2020 vs. Non-GAAP adjusted diluted net earnings per common share for 2021 were $10.05 per share, which represents a 59.0% increase over the comparable 2020 amount. Western Blotting. View Cytiva (www.cytivalifesciences.com) location in Massachusetts, United States , revenue, industry and description. These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt obligations (including the debt incurred to finance the acquisitions of Cytiva and Aldevron) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions (including with respect to the acquisition of Aldevron), our ability to realize anticipated growth, synergies and other benefits of the Aldevron acquisition, Aldevron's performance and maintenance of important business relationships, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance, social and business factors (including the impact of the United Kingdom's separation from the EU), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Final audited financial statements will include footnotes, which should be referenced when available, to more fully understand the contents of this information. Report Scope: The scope of this study entails the worldwide market for thawing systems. 0.13% of the share capital). Revenue 12% Y-o-Y Growth Net Profit 55% Y-o-Y Growth Turnover 2,856 ( in Crore) Our People. Pretax gain on the sale of certain product lines in the Life Sciences segment in the year ended December 31, 2020 ($455 million pretax as reported in this line item, $305 million after-tax). The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of adjusted diluted net earnings from continuing operations per common share. WASHINGTON, Jan. 28, 2021 /PRNewswire/ --Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2020. Cytiva biochemistry and molecular biology products are designed for DNA amplification, nucleic acid, and protein preparation applications. Acquisitions Number of Acquisitions 4 Cytiva has acquired 4 organizations. The company is targeting manufacturers of biologics, vaccines, cell and gene therapies with those upgrades. Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired businesses recorded prior to the first anniversary of the acquisition. Contact Amersham Place, Little Chalfont Buckinghamshire United Kingdom HP7 9NA 0800-515-313 https://www.cytiva.com/ lifesciencescomm@cytiva.com For the first quarter 2021 the Company anticipates that non-GAAP core revenue growth including Cytiva will be in the mid to high-teens range. CONSOLIDATED STATEMENTS OF EARNINGS (unaudited), ($ and shares in millions, except per share amounts), Selling, general and administrative expenses, Loss on early extinguishment of borrowings, Earnings from continuing operations before income taxes, Earnings from discontinued operations, net of income taxes, Mandatory convertible preferred stock dividends, Net earnings attributable to common stockholders. With a rich heritage tracing back over two hundred years, the company joined Danaher in 2020. Management uses these non-GAAP measures to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company's executive compensation program. Non-GAAP adjusted diluted net earnings per common share for 2020 were $6.31 per share, which represents a 43.0% increase over the comparable 2019 amount. How to download CYTIVA INDIA PRIVATE LIMITED report. Such reports can be bought from company pages at Tofler or can be downloaded from Company360. . Competitors and similar companies. Fiscal Year 2021 Annual Report / Audit Report. Annual Report 2020 Primary Menu scroll To our shareholders We have successfully weathered the pandemic so far. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Note: Danaher calculates period-to-period core sales growth including Cytiva by adding Cytiva sales to core sales for both the baseline and current periods. To help facilitate the deal, Danaher divested certain technologies to rival vendor Sartorius . Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. The items we exclude from adjusted diluted net earnings per common share are excluded for the following reasons: With respect to adjusted average common stock and common equivalent shares outstanding, Danaher's Mandatory Convertible Preferred Stock ("MCPS") will mandatorily convert into Danaher common stock on the mandatory conversion date, which is expected to be. 2021. Unless earlier converted, each share of 5.0% MCPS will automatically convert on April 15, 2023 into between 5.0081 and 6.1349 shares of Danaher's common stock, subject to further anti-dilution adjustments. Provider of biopharmaceutical instruments and consumables services intended to advance and accelerate therapeutics. We drive customer-centered . Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the first quarter and full year 2021, role in the fight against COVID-19, positioning to deliver long-term shareholder value and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. Porto Alegre Area, Brazil. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2020 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the third quarter of 2021. Revenues for the full year 2020 increased 24.5% to $22.3 billion, with 9.5% non-GAAP core revenue growth including Cytiva. Contact Data CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For . 2022 Annual Report on Form 10-K. 2023 Merck Proxy Statement. Historically Danaher has calculated core sales solely on a basis that excludes sales from acquired businesses recorded prior to the first anniversary of the acquisition. All results in this release reflect only continuing operations unless otherwise noted. Manufacturing & Industrial - Subsidiary. Adjusted net income of 391 million in 2020, representing 5.11 per share High free cash flow for the year at 651 million, comparable to the level achieved in 2019, reflecting excellent management of working capital (11.8% of sales at 31 December 2020) and strict control of capital expenditure Directly responsible for $9.9 Million in annual revenue in 2015 with 114.63% to plan. Annual and sustainability report 2022 (PDF 8 MB) Year Year (2023) Categories Categories (all) 2023 Annual Report 2020 (13 MB) Auditors' Report & Financial Statements 2020 (in Greek) (3 MB) Annual Report 2019 (7,5 MB) Auditors' Report & Financial Statements 2019 (in Greek) (6,3 MB) Annual Report 2018 (6 MB) Auditors' Report & Financial Statements 2018 (in Greek) (7 MB) Annual Report 2017 (1,5 MB) These factors include, among other things, the highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, Danaher's ability to successfully integrate the operations and employees of the Biopharma business Danaher acquired from General Electric Company (now known as Cytiva) with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits from such acquisition, Cytiva's performance and maintenance of important business relationships, the impact of our debt obligations (including the debt incurred to finance the acquisition of Cytiva) on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's separation from the EU and remaining uncertainty relating to the terms of such separation), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs.